Source comparison
Quick Comparison Table
Peptide class. Ipamorelin is a GHRP pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, ~712 Da). GHRP-6 is a GHRP hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, 873 Da). Receptor target. Both bind the GHS-R1a ghrelin receptor. GH release. Both produce robust, pulsati
This comparison does not assign a generated winner or score.
- Peptide class. Ipamorelin is a GHRP pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, ~712 Da). GHRP-6 is a GHRP hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, 873 Da).
- Receptor target. Both bind the GHS-R1a ghrelin receptor.
- GH release. Both produce robust, pulsatile GH release; GHRP-6 delivers comparable or higher amplitude per injection.
- Cortisol effect. Ipamorelin produces negligible cortisol elevation even at very high doses. GHRP-6 produces modest-to-significant cortisol elevation at doses above approximately 1 mcg/kg.
- Prolactin effect. Ipamorelin has negligible prolactin effect. GHRP-6 shows dose-dependent prolactin elevation above the saturation dose.
- Appetite stimulation. Ipamorelin produces minimal appetite stimulation at standard doses. GHRP-6 produces intense hunger — the strongest of any GHRP.
- Typical dose. Ipamorelin: 100 to 300 mcg per injection, 1 to 3 times daily. GHRP-6: 100 mcg per injection (saturation dose), 2 to 3 times daily.
- Developer and origin. Ipamorelin was developed by Novo Nordisk in the 1990s. GHRP-6 was developed by Cyril Y. Bowers in 1984.
- Regulatory status. Both are not FDA-approved and prohibited by WADA under Section S2.
- Best suited for. Ipamorelin suits clean protocols, fat loss, anti-aging, and combination stacking. GHRP-6 suits mass-building with a caloric surplus or where appetite stimulation is specifically desired.